CompletedPhase 3NCT03591406

To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia

Studying Autosomal recessive sideroblastic anemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vifor (International) Inc.
Principal Investigator
Jie Jin
First Affiliated Hospital of Zhejiang University
Intervention
Ferric carboxymaltose(drug)
Enrollment
371 target
Eligibility
18 years · All sexes
Timeline
20172019

Study locations (1)

Collaborators

Tigermed Consulting Co., Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03591406 on ClinicalTrials.gov

Other trials for Autosomal recessive sideroblastic anemia

Additional recruiting or active studies for the same condition.

See all trials for Autosomal recessive sideroblastic anemia

← Back to all trials